The U.S. House of Representatives passed U.S. Senator Marco Rubio’s (R-FL) Pensacola and Perdido Bays Estuary of National Significance Act (S. 50) to direct the Environmental Protection Agency to formally enroll the Pensacola and Perdido Bays Estuary Program (PPBEP)...
U.S. Senator Marco Rubio (R-FL) released a statement on his nomination by President-elect Donald J. Trump to serve as the United States Secretary of State. “Leading the U.S. Department of State is a tremendous responsibility, and I am honored by the trust President...
U.S. Senator Marco Rubio (R-FL) joined The World Over with Raymond Arroyo to discuss President-elect Donald Trump’s historic victory, the Democrats’ response to the election, foreign policy challenges facing our nation, and more. See below for highlights and watch the...
U.S. Senator Marco Rubio (R-FL) joined America Reports to discuss President-elect Donald Trump’s historic victory, Democrats’ proclamation of “resistance,” and the failure of identity politics. See below for highlights and watch the full interview on YouTube and...
Senator Rubio's office is pleased to be issuing a limited number of tickets to President-elect Donald Trump's inauguration ceremony, which will occur on January 20, 2025 at the West Front of the U.S. Capitol. Floridians interested in receiving tickets should fill out...
U.S. Senator Marco Rubio (R-FL) joined Hannity to discuss President-elect Donald Trump’s historic victory. See below for highlights and watch the full interview on YouTube and Rumble. On the ongoing realignment among American voters: “The Republican Party now reflects...
Washington, D.C. — U.S. Senators Marco Rubio (R-FL), Rick Scott (R-FL), Josh Hawley (R-MO), Ron Johnson (R-WI), Mike Braun (R-IN), Kevin Cramer (R-ND), Cindy Hyde-Smith (R-MS) and Dan Sullivan (R-AK) sent a letter to the president and CEO of Pharmaceutical Research and Manufacturers of America (PhRMA) asking that they provide solutions to address the rising cost of prescription drugs.
El texto de la carta en inglés está aquí. .
Dear Mr. Ubl,
We hear it every day in our states. Drug prices are too high. Patients are paying more and more every year for life-saving drugs, and some are forced to go without those treatments because they simply cannot afford them.
Soaring drug prices are a serious problem and a problem Washington should have addressed long ago. We cannot understand why Americans pay two to six times more than the rest of the world for brand name prescription drugs or why the U.S. comprised 42% of global pharmaceutical revenues based on 2016 data. American consumers should not be subsidizing European countries so they can keep prices low for their consumers. The system needs to change.
Transparency in health care costs is key to giving patients flexibility and control over their health care decisions. American consumers should always come first, and it is time for U.S. companies to be more transparent and bring down the prices of prescription drugs for Americans relative to Canada, Europe and other developed nations.
We write today to ask, as the trade association representing the pharmaceutical industry, what solutions does your association have that would increase transparency and directly lower the list price of drugs for consumers? What specific plans do you have to address price disparities in the international market? And are you willing to work with us to find real solutions to help the American people?
In Washington, there is often too much finger pointing and not enough problem solving. We do not accept that. We are working to find solutions that directly help patients get the health care they deserve. Thank you in advance for your response. We look forward to your cooperation as we work together to lower the cost of prescription drugs.
Atentamente,